Preliminary data are expected this year for a Phase 1/2 clinical trial testing the investigational therapy SRP-1003 in DM1.

We recently published 10 Double-Digit Winners You Wish You Bought Yesterday. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is one of the last week’s top performers. Arrowhead Pharmaceuticals soared by ...

Last week, PureTech Health spun out a new company, Celea Therapeutics, which will develop its pulmonary fibrosis candidate ...

Arrowhead Pharmaceuticals stock tumbled Thursday after Sarepta Therapeutics liquefied its entire stake in the smaller biotech ...

The milestone payment is partially funded through Sarepta’s Arrowhead stock sale as both companies push forward with ...

Sarepta sells $174M in Arrowhead shares to fund a $100M milestone payment as part of its RNAi drug collaboration.

Liquidating its stake in Arrowhead helps Sarepta cover a milestone payment and secure what one analyst described as ...

Sarepta will sell back $50 million worth of shares to cover part of a $100 million milestone payment and its remaining shares worth $174 million.

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) stock fell 6% following Sarepta Therapeutics’ (NASDAQ:SRPT) sale of over 9.2 million Arrowhead shares in a privately negotiated block trade. Sarepta expects ...

Investing.com -- Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) stock dropped 6% after Sarepta Therapeutics (NASDAQ:SRPT) announced it sold over 9.2 million shares of Arrowhead in a privately negotiated ...

Sarepta Therapeutics, the US biotech, has sold around 9.3 million shares of Arrowhead Pharmaceuticals in a privately ...

Piper Sandler analyst Edward Tenthoff reiterated a Buy rating on Inovio Pharmaceuticals today and set a price target of $5.00. The company’s shares closed yesterday at $1.49. El ...